Navigation Links
Xention Reports Positive Phase 1 Data for New Atrial Fibrillation Drug
Date:3/20/2012

eveloper of highly selective ion channel drugs for the treatment of atrial fibrillation.  Utilising its world-leading expertise in the discovery of potent and selective drugs, Xention is focusing on the potassium channels Kv1.5 and IKACh which are widely recognised by cardiologists as the preferred targets for the prevention of atrial fibrillation.  Xention's lead drug candidate XEN-D0103, a Kv1.5 antagonist, is at the end of phase 1 clinical development and has demonstrated a very high degree of selectivity over non-atrial ion channels.  The company has also developed antagonists of IKACh which are highly potent and selective, and an IKACh development candidate will be selected shortly.

Xention has signed two major research collaborations with Ono Pharmaceutical Co Ltd and the Grϋnenthal Group, which take advantage of its strong experience in ion channel discovery and which are focused on the development of clinical candidates in other therapeutic areas.

Xention is based in Cambridge, UK and employs over 50 people. For further information, please visit http://www.xention.com.

For further information, please contact:

Tim Brears, CEO, Xention Limited, +44(0)1223-493-900

Amber Bielecka / Claire Dickinson, M:Communications, xention@mcomgroup.com, +44(0)20-7920-2352


'/>"/>
SOURCE Xention
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. GenVec Reports Fourth Quarter and 2011 Year-End Financial Results
2. EntreMed Reports Fourth Quarter and Year-End 2011 Financial Results
3. Phalanx Biotech Group Reports Robust Revenue Growth in 2011
4. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results
5. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2012
6. Gen-Probe Reports Financial Results for the Fourth Quarter of 2011
7. Neuland Labs Reports Third Quarter Fiscal Year 2012 Financial Results
8. Cepheid Reports Fourth Quarter and Full Year 2011 Results
9. Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M
10. Quest Diagnostics Reports Fourth Quarter 2011 Financial Results; Provides Guidance for 2012
11. Idenix Reports Positive Interim Data for HCV Nucleotide Inhibitor, IDX184
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... ROCKVILLE, Md. , Sept. 30, 2014 /PRNewswire/ ... "RegeneRx") today announced that it has received a ... Aging by Actin-Sequestering Peptides.  This patent includes claims ... and numerous other actin-sequestering peptides for these purposes.  ... About RegeneRx Biopharmaceuticals, Inc. ( www.regenerx.com ) ...
(Date:9/30/2014)... 30, 2014 Fast, semi-automatic ... chemistry in documents ChemAxon , ... consulting services for life science research, launches ChemCurator, ... Markush structures from documents. Markush structures ... however generating and understanding Markush structures is a ...
(Date:9/30/2014)... Los Angeles, CA (PRWEB) September 30, 2014 ... Separation (EWS), the high-speed, chemical-free process to clean up ... letter to shareholders, CEO Riggs Eckelberry reported on the ... West Texas, at a site provided by partner ... ramped up to 1000 barrels per day (bpd) and ...
(Date:9/30/2014)... BioHealth Innovation, Inc. (BHI), a ... and increasing access to early-stage funding in ... Tania Fernandez , Ph.D., has joined the BHI ... a member of the management team for a new ... million in seed and early-stage equity investments to therapeutics, ...
Breaking Biology Technology:RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2OriginOil, Inc. Report to Shareholders: Blue Gold in West Texas 2Seasoned Life Sciences Venture Capitalist Tania Fernandez Joins BHI to Help Manage New BioHealth Gap Fund 2
... FULTON, Miss., March 20, 2012  Frank A. Critz, M.D., founder ... honored with a hometown hero,s welcome this April when he ... prostate cancer survivors.  The event will be April 14, 2012 ... Street in Fulton from noon until 3 p.m., and lunch ...
... DIEGO, March 20, 2012   CareFusion announced today ... Food and Drug Administration (FDA) for its new electrodiagnostic ... EDX system is a multi-modality device for monitoring and ... system. (Logo: http://photos.prnewswire.com/prnh/20100706/CAREFUSIONLOGO ) ...
... LAKE CITY, March 20, 2012 Remedy Informatics, the ... research, announced that Renton, Wash.-based Providence Health & ... registries for their Orthopedic Institute and Telestroke Network to ... http://photos.prnewswire.com/prnh/20120206/SF47874LOGO ) "We are excited to work ...
Cached Biology Technology:Radiotherapy Clinics of Georgia's Founder Returns Home to Celebrate Cancer Survivors and Receive Lifetime Achievement Award 2CareFusion Announces 510(k) Clearance and U.S. Launch of New Advanced Electrodiagnostic System 2Providence Health & Services Inks Deal with Remedy Informatics for Orthopedic and Stroke Registries 2Providence Health & Services Inks Deal with Remedy Informatics for Orthopedic and Stroke Registries 3
(Date:9/30/2014)... any aquatic environment on Earth, but when the climate ... to the limit. The amount of time needed to ... different species cope in the future, reveals a new ... in the scientific journal Proceedings of the Royal ... to increasing levels of greenhouse gases in the atmosphere. ...
(Date:9/30/2014)... in Munich report that a new class of ... chemotherapeutic drugs. They have also pinpointed the relevant ... anti-tumor agents. , Researchers led by LMU,s ... the Technische Universitt Mnchen have identified a class ... in the fight against malignant tumors. The compound ...
(Date:9/30/2014)... , Sept. 30, 2014  Spectra ... solutions for the biotech and power generation ... new RECONN Bioprocess Manager, an easy-to-use and ... geared towards bioprocess development laboratories. ... disparate bioreactor and analyzer systems. Accessing and ...
Breaking Biology News(10 mins):Shape up quickly -- applies to fish, too! 2Cancer therapy: Driving cancer cells to suicide 2Spectra Automation Introduces RECONN Bioprocess Manager 2
... 2012) - The many factors that contribute to how cells ... not fully understood, but researchers at Baylor College of ... intracellular membranes fuse, and in the process, created a new ... the current edition of the journal PLoS Biology . ...
... Cytori Therapeutics (NASDAQ: CYTX) announced today the publication ... Company,s European clinical trial evaluating adipose-derived stem and ... infarction (heart attack or AMI), as Research Correspondence ... of Cardiology . The APOLLO trial was a ...
... (NAS) has awarded John Waterbury, scientist emeritus in the ... the 2012 Gilbert Morgan Smith Medal. Waterbury is ... recognition of their extraordinary scientific achievements in a wide ... sciences. The recipients will be formally recognized in a ...
Cached Biology News:Membrane fusion a mystery no more 2Adipose stem cell heart attack trial data published in JACC 2WHOI's John Waterbury receives NAS Gilbert Morgan Smith Medal 2
... is a 96-well ELISA-compatible plate containing ... (mouse IgG 1 ) is directed ... (GST), and binds with high affinity ... in which the tag is exposed. ...
... Laboratory (RTL) can provide you with ... ,,Microbial method development and validation ,Performance ... conditions of your GMP manufacturing environment ... offer a full spectrum of microbiological ...
... years of experience in the development of ... to large and small peptides, proteins, haptens, ... DNA-encoded antigens. We understand and appreciate that ... development programs are never "cookbook". We will ...
... were designed for full-length gene cloning and ... identify the desired cDNA clone. The first ... "Master Plate," where each well contains plasmid ... positive well(s) by gel electrophoresis of the ...
Biology Products: